Orly Weinreb

Summary

Affiliation: Technion-Israel Institute of Technology
Country: Israel

Publications

  1. Weinreb O, Bar Am O, Prosolovich K, Amit T, Youdim M. Does 1-(R)-aminoindan possess neuroprotective properties against experimental Parkinson's disease?. Antioxid Redox Signal. 2011;14:767-75 pubmed publisher
    ..These observations indicate that 1-(R)-aminoindan may contribute to the overall neuroprotective activity of its parental compound, rasagiline. ..
  2. request reprint
    Weinreb O, Amit T, Bar Am O, Youdim M. Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment. Curr Drug Targets. 2012;13:483-94 pubmed
  3. Bar Am O, Amit T, Youdim M, Weinreb O. Neuroprotective and neurorestorative potential of propargylamine derivatives in ageing: focus on mitochondrial targets. J Neural Transm (Vienna). 2016;123:125-35 pubmed publisher
    ..g., the monoamine oxidase-B inhibitors, selegiline and rasagiline and the multifunctional drugs, ladostigil, M30 and VAR10303) in ageing with a special focus on mitochondrial molecular protective mechanisms. ..
  4. Weinreb O, Mandel S, Bar Am O, Amit T. Iron-chelating backbone coupled with monoamine oxidase inhibitory moiety as novel pluripotential therapeutic agents for Alzheimer's disease: a tribute to Moussa Youdim. J Neural Transm (Vienna). 2011;118:479-92 pubmed publisher
  5. Weinreb O, Amit T, Mandel S, Kupershmidt L, Youdim M. Neuroprotective multifunctional iron chelators: from redox-sensitive process to novel therapeutic opportunities. Antioxid Redox Signal. 2010;13:919-49 pubmed publisher
    ..This review discusses two interrelated approaches concerning therapy targets in neurodegeneration, sharing in common the implementation of iron chelation activity: antioxidation and HIF-1-pathway activation. ..
  6. Badinter F, Amit T, Bar Am O, Youdim M, Weinreb O. Beneficial behavioral, neurochemical and molecular effects of 1-(R)-aminoindan in aged mice. Neuropharmacology. 2015;99:264-72 pubmed publisher
    ..Altogether, the present findings indicate that AI can induce neuroprotective effects on age-related alterations in neurobehavioral functions and exerts neurotrophic up-regulatory and anti-apoptotic properties in aged animals. ..
  7. Golko Perez S, Amit T, Youdim M, Weinreb O. Beneficial Effects of Multitarget Iron Chelator on Central Nervous System and Gastrocnemius Muscle in SOD1(G93A) Transgenic ALS Mice. J Mol Neurosci. 2016;59:504-10 pubmed publisher
  8. Liu W, Lang M, Youdim M, Amit T, Sun Y, Zhang Z, et al. Design, synthesis and evaluation of novel dual monoamine-cholinesterase inhibitors as potential treatment for Alzheimer's disease. Neuropharmacology. 2016;109:376-385 pubmed publisher
  9. Liu W, Rabinovich A, Nash Y, Frenkel D, Wang Y, Youdim M, et al. Anti-inflammatory and protective effects of MT-031, a novel multitarget MAO-A and AChE/BuChE inhibitor in scopolamine mouse model and inflammatory cells. Neuropharmacology. 2017;113:445-456 pubmed publisher
    ..Taken together, these pharmacological properties of MT-031 can be of clinical importance for developing this novel multitarget compound as a novel drug candidate for the treatment of Alzheimer's disease. ..

More Information

Publications11

  1. Weinreb O, Mandel S, Youdim M, Amit T. Targeting dysregulation of brain iron homeostasis in Parkinson's disease by iron chelators. Free Radic Biol Med. 2013;62:52-64 pubmed publisher
  2. Golko Perez S, Mandel S, Amit T, Kupershmidt L, Youdim M, Weinreb O. Additive Neuroprotective Effects of the Multifunctional Iron Chelator M30 with Enriched Diet in a Mouse Model of Amyotrophic Lateral Sclerosis. Neurotox Res. 2016;29:208-17 pubmed publisher
    ..These results suggest that a combination of drug/agents with different, but complementary mechanisms may be beneficial in the treatment of ALS. ..